KR102759447B1 - Zea mays L. pigment No. 5 extract or fraction thereof and uses thereof - Google Patents
Zea mays L. pigment No. 5 extract or fraction thereof and uses thereof Download PDFInfo
- Publication number
- KR102759447B1 KR102759447B1 KR1020230190247A KR20230190247A KR102759447B1 KR 102759447 B1 KR102759447 B1 KR 102759447B1 KR 1020230190247 A KR1020230190247 A KR 1020230190247A KR 20230190247 A KR20230190247 A KR 20230190247A KR 102759447 B1 KR102759447 B1 KR 102759447B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- present
- fraction
- pigment
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000008042 Zea mays Species 0.000 title claims abstract description 61
- 239000000049 pigment Substances 0.000 title claims abstract description 45
- 235000007244 Zea mays Nutrition 0.000 title claims description 16
- 239000000284 extract Substances 0.000 title abstract description 75
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 45
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 45
- 235000005822 corn Nutrition 0.000 claims abstract description 45
- 208000008589 Obesity Diseases 0.000 claims abstract description 30
- 235000020824 obesity Nutrition 0.000 claims abstract description 30
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 235000013305 food Nutrition 0.000 claims description 21
- 102000019280 Pancreatic lipases Human genes 0.000 claims description 20
- 108050006759 Pancreatic lipases Proteins 0.000 claims description 20
- 229940116369 pancreatic lipase Drugs 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 15
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 12
- 235000005911 diet Nutrition 0.000 claims description 7
- 230000037213 diet Effects 0.000 claims description 7
- 239000013589 supplement Substances 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 abstract description 20
- 150000001720 carbohydrates Chemical class 0.000 abstract description 19
- 235000014633 carbohydrates Nutrition 0.000 abstract description 19
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 102000038379 digestive enzymes Human genes 0.000 abstract description 17
- 108091007734 digestive enzymes Proteins 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 230000003579 anti-obesity Effects 0.000 abstract description 10
- 239000003472 antidiabetic agent Substances 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 235000009200 high fat diet Nutrition 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 102000004139 alpha-Amylases Human genes 0.000 description 10
- 108090000637 alpha-Amylases Proteins 0.000 description 10
- 108010028144 alpha-Glucosidases Proteins 0.000 description 10
- 229940024171 alpha-amylase Drugs 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 210000005228 liver tissue Anatomy 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 102000016267 Leptin Human genes 0.000 description 7
- 108010092277 Leptin Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 7
- 229940039781 leptin Drugs 0.000 description 7
- 102000011690 Adiponectin Human genes 0.000 description 6
- 108010076365 Adiponectin Proteins 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000000291 postprandial effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 102000016938 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 229940126904 hypoglycaemic agent Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000006372 lipid accumulation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- -1 troches Substances 0.000 description 3
- 238000004260 weight control Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000605445 Anemarrhena asphodeloides Species 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000946767 Streptomyces toxytricini Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- UJHBVMHOBZBWMX-UHFFFAOYSA-N ferrostatin-1 Chemical compound NC1=CC(C(=O)OCC)=CC=C1NC1CCCCC1 UJHBVMHOBZBWMX-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000020958 lipid digestion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical class CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 탄수화물 또는 지질 소화효소 저해능을 갖는 자색옥수수 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물 및 이의 항비만 및 항당뇨 용도에 관한 것으로, 본 발명에 따른 추출물 또는 이의 분획물은 탄수화물 및 지질 소화효소의 활성을 억제시킴에 따라 탄수화물 및 지질의 체내 흡수를 억제시키는 원리에 의해 비만 및 당뇨를 효과적으로 치료 또는 개선할 수 있다.The present invention relates to an extract of purple corn pigment No. 5 (variety protection application number: Application 2021-185) having a carbohydrate or lipid digestive enzyme inhibitory activity or a fraction thereof and an anti-obesity and anti-diabetic use thereof. The extract or the fraction thereof according to the present invention can effectively treat or improve obesity and diabetes by inhibiting the activity of carbohydrate and lipid digestive enzymes and thereby inhibiting the absorption of carbohydrates and lipids in the body.
Description
본 발명은 자색옥수수 색소5호 추출물 또는 이의 분획물 및 이의 용도에 관한 것으로, 구체적으로 탄수화물 또는 지질 소화효소 저해능을 갖는 자색옥수수 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물 및 이의 항비만 및 항당뇨 용도에 관한 것이다.The present invention relates to an extract of purple corn pigment No. 5 or a fraction thereof and uses thereof, and more particularly, to an extract of purple corn pigment No. 5 (variety protection application number: Application 2021-185) or a fraction thereof having a carbohydrate or lipid digestive enzyme inhibitory effect and its anti-obesity and anti-diabetic uses.
당뇨병은 유전적, 환경적 요인에 의해 인슐린 분비 감소 및 저항성 등과 같이 인슐린 분비에 문제가 있거나 인슐린의 기능에 이상이 생겨 혈액 속의 포도당이 세포로 전달, 저장되지 못하고 혈액 중에 지나치게 많아져 혈당의 수치가 정상인보다 훨씬 높아지는 고혈당증(hyperglycemia) 증상을 보이는 심각한 대사성 질환이다. 당뇨병은 합병증을 포함하여 현재 우리나라 사망원인 중 5번째로 높은 것으로 알려져 있을 만큼 증가하는 추세이다.Diabetes is a serious metabolic disease that occurs when there is a problem with insulin secretion, such as decreased insulin secretion or resistance, due to genetic or environmental factors, or when there is a problem with the function of insulin, so that the glucose in the blood cannot be delivered to the cells and stored, but rather increases excessively in the blood, causing the blood sugar level to be much higher than normal, resulting in symptoms of hyperglycemia. Diabetes is known to be the fifth leading cause of death in Korea, including complications, and is on the rise.
당뇨병에 의한 다양한 합병증으로 인한 환자의 수명은 5~10년 정도 단축되는 것으로 보고되고 있다. 당뇨병 치료의 목표는 당뇨병 환자들의 혈당을 가능한 한 정상혈당으로 유지하는 것이다. 그러나 혈당의 정상유지는 어려운 과제이며, 현재 공복 혈당뿐만 아니라 식후고혈당의 조절이 매우 강조되고 있다. 우리나라 식단의 탄수화물 중 대부분은 전분 형태로 섭취하게 되는데, 전분은 α-아밀라아제 및 α-글루코시다제에 의해 소화된 후 흡수된다. 따라서 α-아밀라아제 또는 α-글루코시다제 저해활성을 가진 물질은 식후 혈당 증가를 억제하여 식후 혈당조절에 도움을 줄 수 있다.It is reported that the life expectancy of patients with diabetes is shortened by 5 to 10 years due to various complications caused by diabetes. The goal of diabetes treatment is to maintain the blood sugar level of diabetic patients as normal as possible. However, maintaining normal blood sugar level is a difficult task, and currently, the control of not only fasting blood sugar but also postprandial hyperglycemia is greatly emphasized. Most of the carbohydrates in the Korean diet are consumed in the form of starch, and starch is digested by α-amylase and α-glucosidase and then absorbed. Therefore, substances with α-amylase or α-glucosidase inhibitory activity can help control postprandial blood sugar by suppressing the increase in postprandial blood sugar.
당뇨병은 진행성 질환으로 초기에는 약으로 조절가능하나 점차적으로 증상이 악화되어 결국에는 인슐린 주사를 투여받아야 한다. 그러나 시간이 경과함에 따라 점점 많은 양의 약물이 요구되고, 부작용이 많기 때문에 이를 예방하기 위해 독성은 없으면서 장기간 당뇨 환자들이 섭취하여도 될 천연물 유래 혈당 조절 기능성 식품에 대한 연구 및 상품화가 시급한 상황이다.Diabetes is a progressive disease that can be controlled with medication in the early stages, but symptoms gradually worsen and eventually require insulin injections. However, as time passes, more and more medications are required, and there are many side effects, so in order to prevent this, there is an urgent need to research and commercialize natural products that are non-toxic and can be consumed by diabetic patients for a long period of time to control blood sugar levels.
한편, 비만은 섭취에너지와 소비에너지의 불균형에 의해 유발되며 이로 인한 에너지 대사 이상으로 지방세포에 중성지방이 과도하게 축적된 상태를 말한다. 최근의 서구화된 식습관으로 인하여 비만 인구가 급격히 증가하고 있으며, 비만의 가장 큰 원인은 고열량이나 고지방을 함유한 음식의 과도한 섭취 및 운동 부족으로 인한 과도한 체내지방 축적이지만, 이외에도 신경 내분비 계통의 이상, 약물, 유전적 요인 및 생화학적 이상 반응에 의해서도 유발되는 것으로 알려졌다.On the other hand, obesity is caused by an imbalance between energy intake and energy expenditure, and refers to a state in which neutral fat is excessively accumulated in fat cells due to abnormal energy metabolism. The obese population has been rapidly increasing due to recent westernized eating habits, and the biggest cause of obesity is excessive intake of high-calorie or high-fat foods and excessive body fat accumulation due to lack of exercise, but it is also known to be caused by abnormalities in the neuroendocrine system, drugs, genetic factors, and biochemical abnormalities.
비만은 외형상의 문제 외에도 고혈압 및 고지혈증, 제2형 당뇨병, 고혈압, 심장질환, 뇌졸중, 관절염, 동맥경화, 암, 대사증후군, 수면무호흡증, 관절염, 요통 등의 만성질환과 밀접한 연관이 있음이 보고되어 있다.In addition to physical problems, obesity has been reported to be closely related to chronic diseases such as hypertension, hyperlipidemia, type 2 diabetes, hypertension, heart disease, stroke, arthritis, arteriosclerosis, cancer, metabolic syndrome, sleep apnea, arthritis, and back pain.
비만의 예방 및 치료에 있어서, 식이요법을 동반한 운동이 가장 적절한 방법이지만 최근에는 비만 치료 및 예방을 보조하기 위한 식욕 억제제, 지방흡수 억제제의 개발이 진행되고 있으며, 그 중에서도 식품 중에 존재하는 트리글리세라이드 (triglyceride)를 약 50~70% 가수분해하여 2-모노아실글리세롤 (2-monoacylglycerol)과 지방산 (fatty acid)으로 분해하는 주요 효소(key enzyme)로 작용하는 췌장 지방 분해효소(pancreatic lipase)의 작용을 억제하는 방법이 주목을 받고 있다.In the prevention and treatment of obesity, exercise combined with diet is the most appropriate method, but recently, appetite suppressants and fat absorption inhibitors have been developed to assist in the treatment and prevention of obesity. Among these, a method of inhibiting the action of pancreatic lipase, a key enzyme that hydrolyzes triglycerides present in foods by about 50-70% and breaks them down into 2-monoacylglycerol and fatty acids, is receiving attention.
현재 항비만 의약품으로 시판중인 립스타틴(lipstatin)의 유도체인 테트라하이드롤립스타틴 (tetrahydrolipstatin; orlistat)은 스트렙토마이시스 톡시트리시니(Streptomyces toxytricini) 균주로부터 유래된 대표적인 췌장 지방 분해효소(pancreatic lipase) 저해물질로서 체내에 섭취된 지방의 소화와 흡수를 억제해 섭취량의 약 30%를 그대로 배설시키는 우수한 효능이 있으나, 최근 위장장애, 과민증, 담즙분비 장애, 지용성 비타민 흡수억제 등의 다양한 부작용이 있는 것으로 보고되고 있다.Tetrahydrolipstatin (orlistat), a derivative of lipstatin currently on the market as an anti-obesity drug, is a representative pancreatic lipase inhibitor derived from the Streptomyces toxytricini strain. It has excellent efficacy in inhibiting the digestion and absorption of fat ingested in the body and excreting about 30% of the ingested amount as it is, but it has recently been reported to have various side effects such as gastrointestinal disorders, hypersensitivity, cholestasis, and inhibition of absorption of fat-soluble vitamins.
이에, 지방 분해효소의 저해능을 갖는 천연 식물 및 화합물에 대한 다양한 연구가 진행되고 있는 실정이다.Accordingly, various studies are being conducted on natural plants and compounds that have the ability to inhibit lipolytic enzymes.
본 발명의 하나의 목적은 탄수화물 또는 지질 소화효소 저해능을 갖는 자색옥수수 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 제공하는데 있다.One object of the present invention is to provide an extract of purple corn pigment No. 5 (variety protection application number: application 2021-185) or a fraction thereof having a carbohydrate or lipid digestive enzyme inhibitory ability.
또한, 본 발명의 또 다른 목적은 본 발명에 따른 추출물 또는 이의 분획물의 항비만 및 항당뇨 용도를 제공하는 것에 있다.In addition, another object of the present invention is to provide anti-obesity and anti-diabetic uses of the extract according to the present invention or a fraction thereof.
본 발명은 자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 제공한다.The present invention provides an extract of purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) or a fraction thereof.
이때, 상기 추출물은, 바람직하게는 정제수, 탄소수 1 내지 4의 저급알코올 및 이들의 혼합용매 중 선택되는 어느 하나의 용매를 이용하여 추출한 것이 좋다.At this time, the extract is preferably extracted using one solvent selected from purified water, lower alcohol having 1 to 4 carbon atoms, and a mixed solvent thereof.
이때, 상기 분획물은, 바람직하게는 자색옥수수 색소 5호 추출물에 헥산(hexane), 메틸렌클로라이드(methylene chloride), 에틸아세테이트(ethyl acetate) 및 부탄올(butanol) 중 선택되는 어느 하나의 용매를 추가로 첨가하여 분획한 것이 좋다.At this time, the fraction is preferably fractionated by additionally adding one solvent selected from hexane, methylene chloride, ethyl acetate, and butanol to the purple corn pigment No. 5 extract.
이때, 상기 추출물 또는 이의 분획물은, 탄수화물 또는 지질 소화효소 저해능을 갖는데, 상기 탄수화물 또는 지질 소화효소는, 바람직하게는 α-아밀라아제(α-amylase), α-글루코시다아제(α-glucosidase) 및 췌장 리파아제(pancreatic lipase)으로 이루어진 군 중 선택되는 어느 하나 이상일 수 있다.At this time, the extract or a fraction thereof has a carbohydrate or lipid digestive enzyme inhibitory ability, and the carbohydrate or lipid digestive enzyme may be preferably at least one selected from the group consisting of α-amylase, α-glucosidase, and pancreatic lipase.
한편, 본 발명은 자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 포함하는 비만 또는 당뇨 예방 또는 치료용 약학 조성물을 제공한다.Meanwhile, the present invention provides a pharmaceutical composition for preventing or treating obesity or diabetes, comprising an extract of purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) or a fraction thereof.
한편, 본 발명은 자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 포함하는 혈당강하제를 제공한다. 이때, 상기 혈당강하제는, 식후 혈당 상승을 억제하는 것일 수 있다.Meanwhile, the present invention provides a hypoglycemic agent comprising an extract of purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) or a fraction thereof. In this case, the hypoglycemic agent may suppress an increase in blood sugar after a meal.
한편, 본 발명은 자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 포함하는 비만 또는 당뇨 예방 또는 개선용 식품 조성물을 제공한다.Meanwhile, the present invention provides a food composition for preventing or improving obesity or diabetes, comprising an extract of purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) or a fraction thereof.
한편, 본 발명은 자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 포함하는 다이어트 보조제를 제공한다.Meanwhile, the present invention provides a diet supplement comprising an extract of purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) or a fraction thereof.
본 발명에 따른 추출물 또는 이의 분획물은 탄수화물 및 지질 소화효소의 활성을 억제시킴에 따라 탄수화물 및 지질의 체내 흡수를 억제시키는 원리에 의해 비만 및 당뇨를 효과적으로 치료 또는 개선할 수 있다.The extract or fraction thereof according to the present invention can effectively treat or improve obesity and diabetes by inhibiting the activity of carbohydrate and lipid digestive enzymes and thereby inhibiting the absorption of carbohydrates and lipids in the body.
도 1은 본 발명에 따른 자색옥수수 색소5호 추출물의 간 조직 내 지질축적 개선 정도를 평가한 결과이다.
도 2는 본 발명에 따른 자색옥수수 색소5호 추출물의 간 조직 내 항산화 활성을 검정한 결과이다.
도 3은 본 발명에 따른 자색옥수수 색소5호 추출물의 체중조절 관련 호르몬인 렙틴(leptin) 및 아디포넥틴(adiponetin)에 관한 분비조절 효능을 확인한 결과이다.Figure 1 shows the results of evaluating the degree of improvement in lipid accumulation in liver tissue by purple corn pigment No. 5 extract according to the present invention.
Figure 2 shows the results of testing the antioxidant activity of purple corn pigment No. 5 extract according to the present invention in liver tissue.
Figure 3 shows the results of confirming the secretion control efficacy of purple corn pigment No. 5 extract according to the present invention on leptin and adiponectin, hormones related to weight control.
하기에서는 중복되는 내용의 혼잡을 방지하기 위하여, 중복되는 내용의 기재를 생략하고자 하였다. 즉, 하기의 내용만으로 발명의 내용이 한정되는 것은 아니고, 전체적인 발명의 내용에 따라 발명의 내용이 해석되어야 할 것이다.In order to avoid confusion due to overlapping content, overlapping content is omitted in the following description. In other words, the content of the invention is not limited to the content below, and the content of the invention should be interpreted according to the content of the entire invention.
본 발명은 자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 제공한다.The present invention provides an extract of purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) or a fraction thereof.
본 발명에서 이용한 자색옥수수(Zea mays L.)는 강원도 농업기술원에서 육종하여 얻어진 품종으로 색소 5호로 명명되어 있으며, 색소 5호는 옥수수 포엽은 자색, 알곡은 황색을 띠는 품종(품종보호 출원번호: 출원 2021-185)이다.The purple corn ( Zea mays L. ) used in the present invention is a variety obtained through breeding at the Gangwon-do Agricultural Research and Extension Services, and is named Pigment No. 5. Pigment No. 5 is a variety with purple corn bracts and yellow grains (variety protection application number: Application 2021-185).
이때, 상기 추출물은, 바람직하게는 정제수, 탄소수 1 내지 4의 저급알코올 및 이들의 혼합용매 중 선택되는 어느 하나의 용매를 이용하여 추출한 것이 좋다.At this time, the extract is preferably extracted using one solvent selected from purified water, lower alcohol having 1 to 4 carbon atoms, and a mixed solvent thereof.
상기 추출물은, 바람직하게 정제수, 탄소수 1 내지 4의 저급알코올 및 이들의 혼합용매 중 선택되는 어느 하나의 용매를 이용하여 추출한 것일 수 있다. 일 예로, 20 내지 40%(v/v)의 에탄올 수용액을 추출 용매로 이용할 수 있고, 바람직하게는 30% 에탄올 수용액으로 추출된 것일 수 있다.The above extract may be extracted using any one solvent selected from purified water, lower alcohols having 1 to 4 carbon atoms, and mixed solvents thereof. For example, a 20 to 40% (v/v) ethanol aqueous solution may be used as the extraction solvent, and preferably, the extract may be extracted using a 30% ethanol aqueous solution.
또한, 상기 추출물은 자색옥수수 원물의 약 1배 내지 20배, 바람직하게는 약 1배 내지 15배의 추출용매를 가하여, 가열 추출, 냉침 추출, 환류 냉각 추출, 또는 초음파 추출로 수행될 수 있다. 이러한 추출은 1시간 내지 24시간, 바람직하게는 3시간 내지 7시간 동안 저온, 상온 또는 고온 조건에서 수행할 수도 있다.In addition, the above extract can be performed by heating extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction by adding about 1 to 20 times, preferably about 1 to 15 times, of the extraction solvent as much as the purple corn raw material. This extraction can be performed under low temperature, room temperature, or high temperature conditions for 1 to 24 hours, preferably 3 to 7 hours.
또한, 상기 추출물은 여과 및/또는 감압농축하여 수득될 수 있으며, 상기 추출 과정을 2 내지 4회 반복하여 여과, 농축, 동결건조, 분무건조 등의 과정을 추가적으로 거칠 수 있다.In addition, the extract can be obtained by filtration and/or concentration under reduced pressure, and the extraction process can be repeated 2 to 4 times, and additional processes such as filtration, concentration, freeze-drying, and spray drying can be performed.
이때, 상기 분획물은, 바람직하게는 자색옥수수 색소 5호 추출물에 헥산(hexane), 메틸렌클로라이드(methylene chloride), 에틸아세테이트(ethyl acetate) 및 부탄올(butanol) 중 선택되는 어느 하나의 용매를 추가로 첨가하여 분획한 것이 좋다.At this time, the fraction is preferably fractionated by additionally adding one solvent selected from hexane, methylene chloride, ethyl acetate, and butanol to the purple corn pigment No. 5 extract.
상기 분획물은 바람직하게는 자색옥수수 색소5호 추출물, 바람직하게는 분말화된 추출물 현탁액에 헥산, 메틸렌클로라이드, 에틸아세테이트 및 부탄올 중 선택되는 어느 하나의 용매를 추가로 첨가하여 분획한 것일 수 있다.The above fraction may be preferably a fraction obtained by further adding a solvent selected from hexane, methylene chloride, ethyl acetate, and butanol to a suspension of a purple corn pigment No. 5 extract, preferably a powdered extract.
이때, 상기 추출물 또는 이의 분획물은, 탄수화물 또는 지질 소화효소 저해능을 갖는데, 상기 탄수화물 또는 지질 소화효소는, 바람직하게는 α-아밀라아제(α-amylase), α-글루코시다아제(α-glucosidase) 및 췌장 리파아제(pancreatic lipase)으로 이루어진 군 중 선택되는 어느 하나 이상일 수 있다.At this time, the extract or a fraction thereof has a carbohydrate or lipid digestive enzyme inhibitory ability, and the carbohydrate or lipid digestive enzyme may be preferably at least one selected from the group consisting of α-amylase, α-glucosidase, and pancreatic lipase.
특히, 본 발명의 일 실시예에 의하면, 본 발명에서 제조한 자색옥수수 색소5호 추출물 및 이의 분획물, 그 중에서도 자색옥수수 색소5호 추출물 및 이의 에틸아세테이트 분획물에서 우수한 탄수화물 또는 지질 소화효소 저해능을 확인한 바 있다.In particular, according to one embodiment of the present invention, it was confirmed that the purple corn pigment No. 5 extract and fractions thereof manufactured in the present invention, particularly the purple corn pigment No. 5 extract and the ethyl acetate fraction thereof, had excellent carbohydrate or lipid digestive enzyme inhibition ability.
전분은 α-아밀라아제 및 α-글루코시다제에 의해 소화된 후 흡수되는데, α-아밀라아제 또는 α-글루코시다제 저해활성을 가진 물질은 식후 혈당 증가를 억제하여 식후 혈당조절에 도움을 줄 수 있다.Starch is digested by α-amylase and α-glucosidase and then absorbed. Substances with α-amylase or α-glucosidase inhibitory activity can help control postprandial blood sugar levels by suppressing the increase in postprandial blood sugar levels.
한편, 식품 중에 존재하는 트리글리세라이드 (triglyceride)를 약 50~70% 가수분해하여 2-모노아실글리세롤 (2-monoacylglycerol)과 지방산 (fatty acid)으로 분해하는 주요 효소(key enzyme)로 작용하는 췌장 지방 분해효소(pancreatic lipase)의 작용의 억제는 비만 치료에 도움을 줄 수 있다.Meanwhile, inhibition of the action of pancreatic lipase, a key enzyme that hydrolyzes about 50-70% of triglycerides present in foods into 2-monoacylglycerol and fatty acids, may help treat obesity.
이에, 본 발명은 본 발명에 따른 자색옥수수 색소5호 추출물 및 이의 분획물의 항당뇨 및 항비만 용도를 제공하고자 한다.Accordingly, the present invention aims to provide anti-diabetic and anti-obesity uses of purple corn pigment No. 5 extract and fractions thereof according to the present invention.
따라서, 본 발명의 하나의 양태는 자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 포함하는 비만 또는 당뇨 예방 또는 치료용 약학 조성물을 제공하는 것에 있다.Accordingly, one aspect of the present invention is to provide a pharmaceutical composition for preventing or treating obesity or diabetes, comprising an extract of purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) or a fraction thereof.
또한, 본 발명의 또 다른 양태는 자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 포함하는 혈당강하제를 제공하는 것에 있다. 이때, 상기 혈당강하제는, 식후 혈당 상승을 억제하는 것일 수 있다.In addition, another aspect of the present invention provides a hypoglycemic agent comprising a purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) extract or a fraction thereof. In this case, the hypoglycemic agent may suppress a rise in blood sugar levels after a meal.
본 발명의 일 실시예에서는 본 발명에 따른 자색옥수수 색소5호 추출물 및 이의 분획물의 우수한 α-아밀라아제(α-amylase), α-글루코시다아제(α-glucosidase) 및 췌장 리파아제(pancreatic lipase) 활성 억제를 통한 항비만 및 항당뇨 효능을 확인한 바 있다.In one embodiment of the present invention, the anti-obesity and anti-diabetic effects of the purple corn pigment No. 5 extract and fractions thereof according to the present invention were confirmed through excellent inhibition of α-amylase, α-glucosidase and pancreatic lipase activities.
본 발명에서 사용되는 용어, "예방"이란 본 발명에 따른 약학적 조성물의 투여에 의해 비만 또는 당뇨를 억제하거나 발병을 지연시키는 모든 행위를 의미한다.The term “prevention” used in the present invention means any act of suppressing or delaying the onset of obesity or diabetes by administering a pharmaceutical composition according to the present invention.
본 발명에서 사용되는 용어, "치료"란 본 발명에 따른 약학적 조성물의 투여에 의해 비만 또는 당뇨에 의한 증세가 호전되거나 이롭게 변경되는 모든 행위를 의미한다.The term "treatment" as used in the present invention means any act by which symptoms of obesity or diabetes are improved or beneficially changed by administration of a pharmaceutical composition according to the present invention.
본 발명은 상기 추출물 또는 이의 분획물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다.The present invention may additionally contain one or more effective ingredients exhibiting the same or similar function as the above extract or fraction thereof.
본 발명의 약학적 조성물은 추출물 또는 이의 분획물 외에 약학적으로 허용 가능한 담체를 추가로 포함할 수 있다.The pharmaceutical composition of the present invention may additionally contain a pharmaceutically acceptable carrier in addition to the extract or a fraction thereof.
본 발명에서 사용될 수 있는 담체의 종류는 특별히 제한되지 아니하며 당해 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용할 수 있다. 상기 담체의 비제한적인 예로는, 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사 용액, 자일리톨, 에리스리톨, 말티톨, 말토덱스트린, 글리세롤, 에탄올 등을 들 수 있다. 이들은 단독으로 사용되거나 2종 이상을 혼합하여 사용될 수 있다.The type of carrier that can be used in the present invention is not particularly limited, and any carrier commonly used in the relevant technical field can be used. Non-limiting examples of the carrier include lactose, dextrose, sucrose, sorbitol, mannitol, saline solution, sterile water, Ringer's solution, buffered saline, albumin injection solution, xylitol, erythritol, maltitol, maltodextrin, glycerol, ethanol, etc. These may be used alone or in combination of two or more.
또한, 본 발명의 약학적 조성물은 필요한 경우, 항산화제, 부형제, 희석제, 완충액 또는 정균제 등 기타 약학적으로 허용 가능한 첨가제들을 첨가하여 사용할 수 있으며, 계면 활성제, 결합제, 충진제, 증량제, 습윤제, 붕해제, 분산제 또는 윤활제 등을 부가적으로 첨가하여 사용할 수 있다.In addition, the pharmaceutical composition of the present invention may be used by adding other pharmaceutically acceptable additives such as antioxidants, excipients, diluents, buffers or bacteriostatic agents, if necessary, and may be used by additionally adding surfactants, binders, fillers, bulking agents, wetting agents, disintegrants, dispersants or lubricants.
본 발명의 약학적 조성물에 있어, 추출물 또는 이의 분획물은 약학적 조성물의 전체의 중량을 기준으로 0.00001 중량％ 내지 99.99 중량％로 포함될 수 있으며, 바람직하게는 0.1 중량% 내지 90 중량%, 보다 바람직하게는 0.1 중량% 내지 70 중량%, 더욱 바람직하게는 0.1 중량% 내지 50 중량%로 포함될 수 있으나, 이에 한정되지 않으며 투여 대상의 상태, 구체적인 병증의 종류, 진행 정도 등에 따라 다양하게 변경될 수 있다. 필요한 경우, 약학적 조성물의 전체 함량으로도 포함될 수 있다.In the pharmaceutical composition of the present invention, the extract or its fraction may be included in an amount of 0.00001 wt% to 99.99 wt% based on the total weight of the pharmaceutical composition, preferably 0.1 wt% to 90 wt%, more preferably 0.1 wt% to 70 wt%, and even more preferably 0.1 wt% to 50 wt%, but is not limited thereto and may vary depending on the condition of the administration subject, the type and degree of specific symptom, etc. If necessary, it may also be included in the total content of the pharmaceutical composition.
즉, 본 발명의 약학적 조성물의 약학적 유효량, 유효 투여량은 약학적 조성물의 제제화 방법, 투여 방식, 투여 시간 및/또는 투여 경로 등에 의해 다양해질 수 있으며, 약학적 조성물의 투여로 달성하고자 하는 반응의 종류와 정도, 투여 대상이 되는 개체의 종류, 연령, 체중, 일반적인 건강 상태, 질병의 증세나 정도, 성별, 식이, 배설, 해당 개체에 동시 또는 이시에 함께 사용되는 약물 기타 조성물의 성분 등을 비롯한 여러 인자 및 의약 분야에서 잘 알려진 유사 인자에 따라 다양해질 수 있으며, 당해 기술 분야에서 통상의 지식을 가진 자는 목적하는 치료에 효과적인 투여량을 용이하게 결정하고 처방할 수 있다. 예를 들어, 본 발명의 약학적 조성물의 일일 투여량은 약 0.0001 내지 1,000㎎/㎏이고, 바람직하게는 0.001 내지 100㎎/㎏이며, 하루 일회 내지 수회에 나누어 투여할 수 있다.That is, the pharmaceutically effective amount, effective dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method of the pharmaceutical composition, the administration method, the administration time, and/or the administration route, and may vary depending on various factors including the type and degree of the response to be achieved by the administration of the pharmaceutical composition, the type, age, weight, general health condition, symptoms or degree of the disease, sex, diet, excretion, drugs used simultaneously or simultaneously in the subject, other components of the composition, and similar factors well known in the medical field, and a person having ordinary knowledge in the relevant technical field can easily determine and prescribe an effective dosage for the intended treatment. For example, the daily dosage of the pharmaceutical composition of the present invention is about 0.0001 to 1,000 mg/kg, preferably 0.001 to 100 mg/kg, and may be administered once or several times a day.
본 발명의 약학적 조성물의 투여는 하루에 1회 투여될 수 있고, 수 회에 나누어 투여될 수도 있다. 본 발명의 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양으로 투여할 수 있으며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition of the present invention may be administered once a day, or may be administered in several divided doses. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. Taking all of the above factors into consideration, it may be administered in an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by those skilled in the art.
본 발명의 약학적 조성물은 비만 또는 당뇨를 예방 또는 치료하기 위하여 추가적으로 호르몬 치료, 약물치료 등의 다양한 방법들과 병용하여 사용될 수 있다.The pharmaceutical composition of the present invention can be additionally used in combination with various methods such as hormone therapy and drug therapy to prevent or treat obesity or diabetes.
본 발명에서 사용된 용어, "투여"는 어떠한 적절한 방법으로 환자에게 본 발명의 약학적 조성물을 도입하는 것을 의미하며, 본 발명의 약학적 조성물의 투여 경로 및 투여 방식은 각각 독립적일 수 있으며, 목적하는 해당 부위에 상기 약학적 조성물이 도달할 수 있는 한, 특별한 제한 없이 임의의 투여 경로 및 투여 방식에 따를 수 있다.The term "administration" used in the present invention means introducing the pharmaceutical composition of the present invention to a patient by any appropriate method, and the administration route and administration method of the pharmaceutical composition of the present invention may each be independent, and any administration route and administration method may be followed without particular limitation, as long as the pharmaceutical composition can reach the desired site.
상기 약학적 조성물은 경구 투여 또는 비경구 투여 방식으로 투여할 수 있으며, 경구 투여 또는 비경구 투여를 위한 적합하고 다양한 제형으로 제제화되어 사용될 수 있다.The above pharmaceutical composition can be administered orally or parenterally, and can be formulated and used in various suitable dosage forms for oral or parenteral administration.
본 발명의 약학적 조성물을 이용한 경구 투여용 제제의 비제한적인 예로는, 유성 현탁액, 트로키제(troches), 로젠지(lozenge), 정제, 수용성 현탁액, 조제 분말, 과립, 에멀젼, 하드 캡슐, 소프트 캡슐, 시럽 또는 엘릭시르제 등을 들 수 있다.Non-limiting examples of oral administration preparations using the pharmaceutical composition of the present invention include oily suspensions, troches, lozenges, tablets, aqueous suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups or elixirs.
본 발명의 약학적 조성물을 경구 투여용으로 제제화하기 위하여, 솔비톨, 만니톨, 전분, 아밀로펙틴, 셀룰로오스 락토오스, 사카로오스 또는 젤라틴 등과 같은 결합제; 스테아르산 마그네슘, 스테아르산 칼슘, 스테아릴 푸마르산 나트륨 또는 폴리에틸렌 글리콜 왁스 등과 같은 윤활유; 디칼슘 포스페이트 등과 같은 부형제; 옥수수 전분 또는 고구마 전분 등과 같은 붕해제 등을 사용할 수 있으며, 방향제, 시럽제, 감미제 등도 사용할 수 있다. 나아가 캡슐제의 경우에는 상기 언급한 물질 외에도 지방유와 같은 액체 담체 등을 추가로 사용할 수 있다.In order to formulate the pharmaceutical composition of the present invention for oral administration, a binder such as sorbitol, mannitol, starch, amylopectin, cellulose, lactose, saccharose or gelatin; a lubricant such as magnesium stearate, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax; an excipient such as dicalcium phosphate; a disintegrant such as corn starch or sweet potato starch; and a flavoring agent, syrup, sweetener, etc. can also be used. Furthermore, in the case of capsules, in addition to the above-mentioned substances, a liquid carrier such as fatty oil can be additionally used.
본 발명의 약학적 조성물의 비경구 투여 방법으로는, 근육 내 투여, 경피 투여, 정맥 내 투여, 복강 내 투여 또는 피하 투여 등을 이용할 수 있으며, 상기 조성물을 질환 부위에 도포하거나 분무, 흡입하는 방법 또한 이용할 수 있으나 이에 제한되지 않는다.As a parenteral administration method of the pharmaceutical composition of the present invention, intramuscular administration, transdermal administration, intravenous administration, intraperitoneal administration, or subcutaneous administration may be used, and a method of applying, spraying, or inhaling the composition to the diseased area may also be used, but is not limited thereto.
본 발명의 약학적 조성물을 이용한 비경구용 제제의 비제한적인 예로는, 주사액, 좌제, 연고, 도포용 파우더, 오일, 호흡기 흡입용 분말, 스프레이용 에어로졸제, 크림 등을 들 수 있다.Non-limiting examples of parenteral preparations using the pharmaceutical composition of the present invention include injections, suppositories, ointments, powders for application, oils, powders for respiratory inhalation, aerosols for sprays, creams, etc.
본 발명의 약학적 조성물을 비경구 투여용으로 제제화하기 위하여, 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결 건조 제제, 외용제 등을 사용할 수 있으며, 상기 비수성용제, 현탁제로는 올리브 오일과 같은 식물성 기름, 프로필렌글리콜, 폴리에틸렌글리콜, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.In order to formulate the pharmaceutical composition of the present invention for parenteral administration, a sterile aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a freeze-dried preparation, an external preparation, etc. can be used. As the non-aqueous solvent and suspension, a vegetable oil such as olive oil, propylene glycol, polyethylene glycol, an injectable ester such as ethyl oleate, etc. can be used.
본 발명의 약학적 조성물을 주사액으로 제제화하는 경우, 본 발명의 약학적 조성물을 안정제 또는 완충제와 함께 물에서 혼합하여 용액 또는 현탁액으로 제조하고 이를 앰플(ampoule) 또는 바이알(vial)의 단위 투여용으로 제제화할 수 있다.When the pharmaceutical composition of the present invention is formulated as an injection, the pharmaceutical composition of the present invention may be prepared as a solution or suspension by mixing it in water with a stabilizer or buffer, and this may be formulated for unit dose in an ampoule or vial.
본 발명의 약학적 조성물을 에어로졸제로 제제화하는 경우, 수분산된 농축물 또는 습윤 분말이 분산되도록 추진제 등이 첨가제와 함께 배합할 수 있다.When the pharmaceutical composition of the present invention is formulated as an aerosol, a propellant or the like can be mixed together with additives so that the water-dispersed concentrate or wet powder can be dispersed.
본 발명의 약학적 조성물을 연고, 오일, 크림, 도포용 파우더, 피부 외용제 등으로 제제화하는 경우에는, 동물성 유, 식물성 유, 왁스, 파라핀, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 전분, 트라칸트, 셀룰로오스 유도체, 산화 아연 등을 담체로 사용하여 제제화할 수 있다.When the pharmaceutical composition of the present invention is formulated as an ointment, oil, cream, powder for application, external skin preparation, etc., animal oil, vegetable oil, wax, paraffin, polyethylene glycol, silicone, bentonite, silica, talc, starch, tragacanth, cellulose derivatives, zinc oxide, etc. can be used as a carrier for formulation.
한편, 본 발명의 또 다른 양태는 자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 포함하는 비만 또는 당뇨 예방 또는 개선용 식품 조성물을 제공하는 것에 있다.Meanwhile, another aspect of the present invention is to provide a food composition for preventing or improving obesity or diabetes, comprising an extract of purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) or a fraction thereof.
또한, 본 발명의 또 다른 양태는 자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185) 추출물 또는 이의 분획물을 포함하는 다이어트 보조제를 제공하는 것에 있다.In addition, another aspect of the present invention is to provide a diet supplement comprising a purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) extract or a fraction thereof.
즉, 본 발명에 따른 식품 조성물은 다이어트 보조제를 포함한다.That is, the food composition according to the present invention includes a diet supplement.
본 발명의 식품 조성물에 있어, 추출물 또는 이의 분획물 함량은 특별히 제한되지 않으며, 투여 대상의 상태, 구체적인 병증의 종류, 진행 정도 등에 따라 다양하게 변경될 수 있다. 필요한 경우, 식품의 전체 함량으로도 포함될 수 있다.In the food composition of the present invention, the content of the extract or fraction thereof is not particularly limited, and may be varied in various ways depending on the condition of the subject of administration, the type of specific disease, the degree of progression, etc. If necessary, it may also be included as the total content of the food.
본 발명의 식품 조성물은 일 예로, 면류, 껌류, 유제품류, 아이스크림류, 육류, 곡류, 카페인 음료, 일반음료, 초콜릿, 빵류, 스낵류, 과자류, 사탕, 피자, 젤리, 알코올성 음료, 술, 비타민 복합제 및 그 밖의 건강보조식품류 중 선택되는 어느 하나일 수 있으나, 반드시 이에 한정되는 것은 아니다.The food composition of the present invention may be, for example, any one selected from among noodles, gum, dairy products, ice cream, meat, grains, caffeinated beverages, general beverages, chocolate, bread, snacks, confectionery, candy, pizza, jelly, alcoholic beverages, alcohol, vitamin complexes, and other health supplements, but is not necessarily limited thereto.
본 발명의 식품 조성물이 식품 첨가물의 형태로 사용될 경우, 이를 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.When the food composition of the present invention is used in the form of a food additive, it can be added as is or used together with other foods or food ingredients, and can be used appropriately according to a conventional method.
또한, 본 발명의 "식품 조성물"은 건강기능식품을 포함하는 의미를 포괄하는데, 상기 "건강기능식품"이라 함은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.In addition, the "food composition" of the present invention encompasses the meaning including health functional food, wherein the "health functional food" means a food manufactured and processed using raw materials or ingredients having functionality useful to the human body according to Act No. 6727 on Health Functional Food, and "functionality" means consuming for the purpose of obtaining a useful effect for health purposes such as regulating nutrients for the structure and function of the human body or physiological effects.
본 발명의 식품 조성물은 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예들 들어, 비오틴(biotin), 폴레이트(folate), 판토텐산(pantothenic acid), 비타민 A, C, D, E, B1, B2, B6, B12, 나이아신(niacin) 등을 포함할 수 있다. 또한, 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu), 아연(Zn), 철(Fe), 칼슘(Ca) 등의 미네랄을 포함할 수 있다. 또한, 시스테인, 발린, 라이신, 트립토판 등의 아미노산을 포함할 수 있다. 또한, 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 디히드로초산나트륨 등), 착색제(타르색소 등), 발색제(아질산나트륨, 아초산나트륨 등), 표백제(아황산나트륨), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨루엔(BHT) 등), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 첨가할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용될 수 있다.The food composition of the present invention may contain additional ingredients that are commonly used to improve odor, taste, sight, etc. For example, it may contain biotin, folate, pantothenic acid, vitamins A, C, D, E, B1, B2, B6, B12, niacin, etc. In addition, it may contain minerals such as chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), zinc (Zn), iron (Fe), calcium (Ca), etc. In addition, it may contain amino acids such as cysteine, valine, lysine, and tryptophan. In addition, food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), coloring agents (tar color, etc.), coloring agents (sodium nitrite, sodium nitrate, etc.), bleaching agents (sodium sulfite), bactericides (bleaching powder and high-purity bleaching powder, sodium hypochlorite, etc.), leavening agents (alum, D-potassium hydrogen tartrate, etc.), reinforcing agents, emulsifiers, thickeners (glucose), film-forming agents, antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), seasonings (MSG, monosodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), gum bases, antifoaming agents, solvents, and improvers can be added. The above additives can be selected depending on the type of food and used in an appropriate amount.
이하, 본 발명의 구성을 하기 실시예를 통해 구체적으로 설명하고자 한다. 다만, 본 발명의 권리범위가 하기 실시예에만 한정되는 것은 아니고, 그와 등가의 기술적 사상의 변형까지를 포함한다.Hereinafter, the composition of the present invention will be specifically explained through the following examples. However, the scope of the rights of the present invention is not limited to the following examples, but includes modifications of technical ideas equivalent thereto.
[[ 실시예Example 1:1: 자색옥수수Purple corn 색소5호Pigment No. 5 추출물의 제조]Preparation of extracts]
자색옥수수(Zea mays L.) 색소5호 (품종보호 출원번호: 출원 2021-185)의 건조된 포엽 1 ㎏을 조분쇄하여 30%(v/v) 에탄올 수용액으로 5시간씩 2회 상온 교반 추출하였다. 그 후 와트만(Whatman) #4 여과지로 여과하고 감압 농축하여 자색옥수수 색소5호 추출물을 제조하였다.1 kg of dried bracts of purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: Application 2021-185) were crushed and extracted twice with 30% (v/v) ethanol aqueous solution at room temperature for 5 hours each. After that, the extract was filtered through Whatman #4 filter paper and concentrated under reduced pressure to produce purple corn pigment No. 5 extract.
[[ 실시예Example 2 내지 5: 2 to 5: 자색옥수수Purple corn 색소5호Pigment No. 5 추출물 Extract 분획물의of the fraction 수득][Obtained]
상기 실시예 1에서 얻은 자색옥수수 색소5호 추출물을 정제수에 현탁한 다음, 헥산(실시예 2), 메틸렌클로라이드(실시예 3), 에틸아세테이트(실시예 4) 및 부탄올(실시예 5) 순서대로 용매분획을 수행하여, 각각의 분획물을 수득하였다.The purple corn pigment No. 5 extract obtained in the above Example 1 was suspended in purified water, and solvent fractionation was performed in the following order: hexane (Example 2), methylene chloride (Example 3), ethyl acetate (Example 4), and butanol (Example 5), to obtain each fraction.
[[ 실험예Experimental example 1: 탄수화물 1: Carbohydrates 및 지질and lipids 소화효소 저해 활성 평가][Evaluation of digestive enzyme inhibition activity]
지질 소화효소 저해활성은 췌장 리파아제(pancreatic lipase) 효소의 저해정도를 측정하였으며, 실험은 Kwon 등(Korean J Food Preserv. 21(3), 421-426 (2014); antioxidant and pancreatic lipase inhibitory activities of Anemarrhena asphodeloides)의 논문을 참고하여 수행하였다.Lipid digestion enzyme inhibitory activity was measured by the degree of inhibition of pancreatic lipase enzyme, and the experiment was performed with reference to the paper of Kwon et al. (Korean J Food Preserv. 21(3), 421-426 (2014); antioxidant and pancreatic lipase inhibitory activities of Anemarrhena asphodeloides ).
실시예 1의 자색옥수수 색소5호 추출물 및 실시예2 내지 5의 분획물을 버퍼 또는 증류수에 녹인 시료를 농도별로 희석하여 췌장 리파아제의 활성을 50% 저해(IC50)하는 농도를 산출하여 그 결과를 하기 표 1에 나타내었다.Samples containing the purple corn pigment No. 5 extract of Example 1 and the fractions of Examples 2 to 5 dissolved in buffer or distilled water were diluted according to concentration to calculate the concentration that inhibited pancreatic lipase activity by 50% (IC 50 ). The results are shown in Table 1 below.
(㎎/㎖)(mg/ml)
실험 결과, 실시예 1의 자색옥수수 색소5호 추출물 및 실시예2 내지 5의 분획물 모두는 췌장 리파아제(pancreatic lipase)에 관한 저해활성이 우수한 것으로 확인되었다. 특히, 실시예 1의 자색옥수수 색소5호 추출물 및 실시예 4의 에틸아세테이트 분획물은 저농도 처리군에서도 우수한 췌장 리파아제(pancreatic lipase)에 관한 저해활성을 보여, 지질 소화효소 저해능이 특히 우수한 것으로 확인되었다.As a result of the experiment, it was confirmed that the purple corn pigment No. 5 extract of Example 1 and the fractions of Examples 2 to 5 all had excellent inhibitory activity against pancreatic lipase. In particular, the purple corn pigment No. 5 extract of Example 1 and the ethyl acetate fraction of Example 4 showed excellent inhibitory activity against pancreatic lipase even in the low-concentration treatment group, confirming that their lipid digestive enzyme inhibition ability was particularly excellent.
이에, 하기에서는 췌장 리파아제(pancreatic lipase)에 관한 저해활성이 가장 우수하게 나타난, 실시예 4의 에틸아세테이트 분획물의 탄수화물 및 지질 소화효소 활성 저해효능을 확인하고자 하였다.Accordingly, the following was conducted to confirm the carbohydrate and lipid digestive enzyme activity inhibition efficacy of the ethyl acetate fraction of Example 4, which showed the best inhibitory activity against pancreatic lipase.
탄수화물 소화효소 저해 활성은 시료 첨가에 따른 α-아밀라아제와 α- 글루코시다아제 효소의 저해정도를, 지질 소화효소 저해활성은 췌장 리파아제 효소의 저해정도를 측정하였으며, 실험은 Kwon 등(Korean J Food Preserv. 21(3), 421-426 (2014); antioxidant and pancreatic lipase inhibitory activities of Anemarrhena asphodeloides)과 Hwang 등(J Korean Soc Food Sci Nutr 36(8), 989-994 (2007); 조릿대잎 추출물의 탄수화물 소화효소활성 저해 및 식후혈당강하효과)의 논문을 참고하여 수행하였다.Carbohydrate digestive enzyme inhibition activity was measured by the degree of inhibition of α-amylase and α-glucosidase enzymes according to the addition of samples, and lipid digestive enzyme inhibition activity was measured by the degree of inhibition of pancreatic lipase enzyme. The experiment was performed with reference to the papers of Kwon et al. (Korean J Food Preserv. 21(3), 421-426 (2014); antioxidant and pancreatic lipase inhibitory activities of Anemarrhena asphodeloides ) and Hwang et al. (J Korean Soc Food Sci Nutr 36(8), 989-994 (2007); carbohydrate digestive enzyme inhibition and postprandial blood glucose lowering effect of reed leaf extract).
분획물 시료는 버퍼 또는 증류수에 용해시킨 후 분석시료로 사용하였고, 녹인 시료를 농도별로 희석하여 지질 및 탄수화물 소화효소의 활성을 50% 저해(IC50)하는 농도를 산출하여 그 결과를 하기 표 2에 나타내었다.The fraction samples were dissolved in buffer or distilled water and used as analysis samples. The dissolved samples were diluted according to concentration to calculate the concentration that inhibited the activity of lipid and carbohydrate digestive enzymes by 50% (IC 50 ). The results are shown in Table 2 below.
실험 결과, 실시예 4의 에틸아세테이트 분획물은 지질 소화효소인 췌장 리파아제(pancreatic lipase), 탄수화물 소화효소인 α-아밀라아제(α-amylase) 및 α-글루코시다아제(α-glucosidase) 모두에 대하여 우수한 저해활성을 갖는 것으로 확인되었다.As a result of the experiment, it was confirmed that the ethyl acetate fraction of Example 4 had excellent inhibitory activity against pancreatic lipase, a lipid-digesting enzyme, and α-amylase and α-glucosidase, carbohydrate-digesting enzymes.
[[ 실험예Experimental example 2: 2: 항비만Anti-obesity 활성 평가][Active Evaluation]
본 발명에서는 상기 실험예 1에서 탄수화물 및 지질 소화효소에 관한 우수한 효능을 확인한 실시예 1의 자색옥수수 색소5호 추출물 및 실시예 4의 에틸아세테이트 분획물 중에서 그 효능이 보다 적게 나타난 실시예 1의 자색옥수수 색소5호 추출물을 대표적으로 선택하여 실험을 수행하였다.In the present invention, among the purple corn pigment No. 5 extract of Example 1 and the ethyl acetate fraction of Example 4, which confirmed excellent efficacy with respect to carbohydrate and lipid digestive enzymes in the above Experimental Example 1, the purple corn pigment No. 5 extract of Example 1, which showed a lower efficacy, was selected as a representative and an experiment was conducted.
따라서, 하기에서 확인되는 실시예 1의 자색옥수수 색소5호 추출물의 항비만 활성 결과로부터 실시예 4의 에틸아세테이트 분획물의 항비만 활성이 이와 동일 또는 보다 우수하게 나타날 것임을 쉽게 판단할 수 있다.Therefore, it can be easily judged from the anti-obesity activity results of the purple corn pigment No. 5 extract of Example 1 confirmed below that the anti-obesity activity of the ethyl acetate fraction of Example 4 will be the same as or better.
1. 비만 모델의 제작1. Creation of an obesity model
비만 모델의 제작을 위하여 3주령의 SD-Rat를 이용하였고, 시료로는 실시예 1의 자색옥수수 색소5호 추출물의 분무건조물을 이용하였다.To produce an obesity model, 3-week-old SD-rats were used, and the spray-dried product of purple corn pigment No. 5 extract of Example 1 was used as a sample.
구체적으로, 고지방식이 (제조 사료: 지방 45%)를 통해 비만을 유발한 SD-Rat에 실시예 1의 추출 분무건조물을 농도별로 8주간 매일 일정 시간에 위 내 경구 투여하였다.Specifically, the spray-dried extract of Example 1 was orally administered intragastrically at various concentrations at a set time every day for 8 weeks to SD-rats induced to have obesity through a high-fat diet (manufactured feed: 45% fat).
이에 따른 구체적인 모델군은 하기 표 3에 나타내었다.The specific model groups according to this are shown in Table 3 below.
2. 체중 및 사료 섭취량 평가2. Evaluation of body weight and feed intake
체중 및 음수, 사료 섭취량은 매주 1회(총 8회) 측정하였다. 식이섭취량과 체중은 매일 오전 동일한 시간에 측정하고, 식이 효율 (Food Efficiency Ratio: FER)은 총 체중 증가량을 총 식이섭취량으로 나눈 값으로 산출하였고, 그 결과를 하기 표 4에 나타내었다.Body weight, water intake, and feed intake were measured once a week (total of 8 times). Food intake and body weight were measured at the same time every morning, and the food efficiency ratio (FER) was calculated by dividing the total body weight gain by the total food intake, and the results are shown in Table 4 below.
1) FER(food efficiency ratio): 체중 증가량(body weight gain)/음식 섭취량(food intake). 1) FER (food efficiency ratio): body weight gain / food intake.
2) 해당 값은 각 그룹당 6마리 쥐의 평균±SD임. 2) The values are the mean ± SD of 6 mice per group.
3) 열 내 위첨자가 다른 값은 덩컨 다중범위 검정으로 유의한 차이 (p<0.05)를 나타냄. 3) Values with different superscripts within a column indicate significant differences (p<0.05) as determined by Duncan multiple range test.
실험 결과, 고지방식이로 인하여 대조군의 체중이 정상군 대비 약 17% 증가하였으며, 실시예 1의 추출물의 투여로 체중 증가율이 유의적으로 감소한 것으로 확인되었다.As a result of the experiment, it was confirmed that the body weight of the control group increased by approximately 17% compared to the normal group due to the high-fat diet, and the weight gain rate was significantly reduced by administration of the extract of Example 1.
또한, 각 실험군별 식이섭취량의 유의적인 차이는 없었으나 체중증가량 대비 식이섭취량을 나타내는 식이효율(FER)에서 차이가 나타났다. 이러한 결과는 실시예 1의 추출물의 투여로 비만유발 대조군 대비 식이효율이 유의적으로 감소되었음을 의미한다.In addition, although there was no significant difference in the amount of food intake between each experimental group, there was a difference in the feed efficiency ratio (FER), which indicates the amount of food intake compared to the amount of weight gain. These results indicate that the feed efficiency significantly decreased compared to the obesity-induced control group due to the administration of the extract of Example 1.
3. 장기 무게 측정3. Long-term weight measurement
해부 및 조직 처리를 위하여 비만 유발과 동시에 8주 동안 시료를 경구 투여한 후, 마지막 투여 시간으로부터 12시간 절식을 시킨 뒤 CO2 가스로 마취시켰다. 이후 개복을 하여 복강대동맥에서 혈액을 채취하고, 간 문맥을 통하여 생리식염수를 주입하여 간 내의 혈액을 제거한 후 장기를 적출하였다. 지방조직은 후복강 지방조직 (retroperitoneal adiposetissue), 장간막 지방(mesenteric fat), 부고환 지방조직(epididymal adipose tissue)을 분리하고, 견갑골 사이의 갈색지방(brown adipose tissue)을 분리하여 무게를 측정하여 하기 표 5에 나타내었다.For dissection and tissue processing, the samples were administered orally for 8 weeks simultaneously with obesity induction, and then fasted for 12 hours from the last administration time and anesthetized with CO2 gas. After that, the laparotomy was performed, blood was collected from the celiac aorta, and saline was injected through the hepatic portal vein to remove blood in the liver, and the organs were removed. The retroperitoneal adipose tissue, mesenteric fat, and epididymal adipose tissue were separated, and the brown adipose tissue between the scapulae was separated and the weight was measured, which is shown in Table 5 below.
1) 해당 값은 각 그룹당 6마리 쥐의 평균±SD임. 1) The values are the mean ± SD of 6 mice per group.
2) 열 내 위첨자가 다른 값은 덩컨 다중범위 검정으로 유의한 차이를 나타냄. 2) Values with different superscripts within a column indicate significant differences as determined by the Duncan multiple range test.
실험 결과, 고지방식이로 인하여 대조군의 간 및 부고환지방의 무게가 증가한 것으로 확인되었으며, 실시예 1의 추출물(특히, T3군) 투여로 간과 부고환지방 무게가 유의적으로 감소하였다.As a result of the experiment, it was confirmed that the weight of the liver and epididymal fat in the control group increased due to the high-fat diet, and the weight of the liver and epididymal fat significantly decreased with administration of the extract of Example 1 (especially, the T3 group).
4. 생화학적 분석4. Biochemical analysis
혈액채취는 비만 유발과 동시에 8주 동안 시료를 경구 투여한 후, 마지막 투여 시간으로부터 12시간 절식을 시킨 뒤 CO2 가스로 마취시켰다. 이후 개복하여 복강대동맥에서 혈액을 채취한 뒤 원심 분리기를 이용하여 3,000 rpm으로 15분간 분리한 후, 혈청은 분석 직전까지 -70℃에서 보관하였다.Blood collection was performed by administering samples orally for 8 weeks simultaneously with obesity induction, fasting for 12 hours from the last administration time, and anesthetizing with CO2 gas. Afterwards, the laparotomy was performed, blood was collected from the abdominal aorta, and separated using a centrifuge at 3,000 rpm for 15 minutes. The serum was stored at -70℃ until immediately before analysis.
AST(aspartate aminotransferase), ALT(alanine aminotransferase), T-CHO(총콜레스테롤) 및 중성지방(TG) 수치를 측정하여 하기 표 6에 나타내었다.AST (aspartate aminotransferase), ALT (alanine aminotransferase), T-CHO (total cholesterol), and triglyceride (TG) levels were measured and shown in Table 6 below.
1) 해당 값은 각 그룹당 6마리 쥐의 평균±SD임. 1) The values are the mean ± SD of 6 mice per group.
2) 열 내 위첨자가 다른 값은 덩컨 다중범위 검정으로 유의한 차이를 나타냄. 2) Values with different superscripts within a column indicate significant differences as determined by the Duncan multiple range test.
AST 및 ALT는 간세포 내에 존재하는 효소들로 주로 간세포가 손상을 받는 경우에 혈중으로 방출되어 혈중 수치가 증가하게 된다. 그 외에 약물 복용, 비알코올성 지방간 및 비만 등에서도 만성적으로 높아져 있을 수 있는데, 비만유발에 의해 증가된 혈청 내 AST 함량이 실시예 1 추출물의 투여로 인해 유의적으로 감소하였음을 확인하였다.AST and ALT are enzymes that exist in liver cells, and are mainly released into the blood when liver cells are damaged, causing blood levels to increase. In addition, they can be chronically elevated due to drug use, non-alcoholic fatty liver disease, and obesity. It was confirmed that the serum AST content increased by obesity-induced obesity was significantly reduced by administration of the extract of Example 1.
한편, 총콜레스테롤 및 중성지방은 고지방식이 투여로 인하여 정상군 대비 증가하였으며, 총콜레스테롤은 정상군을 제외하고 실험군간 유의성은 없으며, 중성지방은 추출물의 투여로 대조군 대비 수치의 차이는 있었으나 농도 상관관계는 나타나지 않았다.Meanwhile, total cholesterol and neutral fat increased compared to the normal group due to high-fat diet administration, and there was no significant difference in total cholesterol between the experimental groups except for the normal group, and neutral fat showed a difference in value compared to the control group due to extract administration, but no correlation was observed with concentration.
5. 간 조직 내 지질축적 측정5. Measurement of lipid accumulation in liver tissue
간조직 내 지질과산화물 함량은 TBA(thiobarbituric acid)와 반응하는 MDA(malondialdehyde, (1,1,3,3-tetraethoxypropane)의 농도를 측정함으로써 확인하였다. 지질과산화 반응의 생성물인 MDA의 함량은 간 조직의 과산화적 손상 지표로 사용된다.The lipid peroxide content in liver tissue was determined by measuring the concentration of MDA (malondialdehyde, (1,1,3,3-tetraethoxypropane)) which reacts with TBA (thiobarbituric acid). The content of MDA, a product of lipid peroxidation reaction, is used as an indicator of oxidative damage to liver tissue.
실험 결과, 실시예 1의 추출물 5 ㎎/㎏ 투여군(T1)을 제외하고 대조군 대비 유의적으로 MDA 수치가 현저히 낮은 것으로 나타났다 (도 1). 도 1은 본 발명에 따른 자색옥수수 색소5호 추출물의 간 조직 내 지질축적 개선 정도를 평가한 결과이다.As a result of the experiment, it was shown that the MDA level was significantly lower than that of the control group, except for the group (T1) administered 5 mg/kg of the extract of Example 1 (Figure 1). Figure 1 shows the results of evaluating the degree of improvement in lipid accumulation in liver tissue by the purple corn pigment No. 5 extract according to the present invention.
이러한 결과는 실시예 1의 추출물 투여로 간 고지방식이로 인한 간지질 축적이 억제되었음을 의미한다.These results indicate that the administration of the extract of Example 1 inhibited the accumulation of hepatic lipids induced by a high-fat diet.
6. 간 조직 내 항산화 활성 검정6. Antioxidant activity assay in liver tissue
간조직 내 항산화 활성은 CAT(catalase) 및 GSH(glutathione)의 농도를 측정함으로써 확인하였다. CAT는 체내 활성 산소를 분해하는 작용을 하는 효소이며, GSH는 산화-환원 반응에 중요한 역할을 하는 항산화 물질이다.Antioxidant activity in liver tissue was confirmed by measuring the concentrations of CAT (catalase) and GSH (glutathione). CAT is an enzyme that decomposes active oxygen in the body, and GSH is an antioxidant that plays an important role in oxidation-reduction reactions.
실험 결과, 고지방식이 투여로 인하여 비만이 유발된 대조군의 CAT와 GSH 함량은 정상군 대비 유의적으로 낮은 수치를 나타내었다. 이러한 결과는 비만 유발로 인한 체내 항산화 시스템의 불균형을 의미한다.As a result of the experiment, the CAT and GSH contents of the control group, which was induced obese by high-fat diet administration, were significantly lower than those of the normal group. These results imply an imbalance in the body's antioxidant system due to obesity.
한편, CAT 효소 활성은 실시예 1의 추출물 25 ㎎/㎏ 투여군에서 대조군보다 유의적으로 높은 활성 수치를 나타내었으나 추출물 투여 농도 간의 상관관계는 나타나지 않았다. GSH 함량은 실시예 1의 추출물 5 ㎎/㎏ 투여군이 대조군보다 유의적으로 높은 함량(약 25%)을 나타내었으나 추출물의 농도 의존적 경향은 보이지 않았다 (도 2). 도 2는 본 발명에 따른 자색옥수수 색소5호 추출물의 간 조직 내 항산화 활성을 검정한 결과이다.Meanwhile, CAT enzyme activity showed a significantly higher activity level in the group administered 25 mg/kg of the extract of Example 1 than in the control group, but there was no correlation between the administered concentrations of the extract. GSH content showed a significantly higher content (approximately 25%) in the group administered 5 mg/kg of the extract of Example 1 than in the control group, but there was no concentration-dependent tendency of the extract (Fig. 2). Fig. 2 shows the results of testing the antioxidant activity of the purple corn pigment No. 5 extract according to the present invention in liver tissue.
7. 체중조절 관련 호르몬 측정7. Measurement of hormones related to weight control
간조직 내 항산화 활성은 렙틴(leptin) 및 아디포넥틴(adiponetin)의 농도를 측정함으로써 확인하였다. 렙틴은 지방세포에서 분비되는 호르몬으로 물질대사와 식욕억제, 에너지소비 조절 등에 관여하며 체내 지방조직의 양과 비례하여 혈중으로 분비된다. 체내 렙틴의 부족은 비만과 지방간을 유발하고, 에너지 과잉 섭취 시 식욕 억제를 위해 생성되는 호르몬으로 비만의 지표로 사용된다. 한편, 아디포넥틴은 지방세포에서 분비되는 호르몬으로 지방 및 포도당 대사에 관여하며 체내 체질량 지수와 음의 상관관계를 나타낸다. 체내 중성지방이 높은 비만 또는 대사증후군에서 아디포넥틴의 수치가 감소되는 것으로 보고되었다.Antioxidant activity in liver tissue was confirmed by measuring the concentrations of leptin and adiponectin. Leptin is a hormone secreted from adipocytes and is involved in metabolism, appetite suppression, and energy consumption control, and is secreted into the blood in proportion to the amount of adipose tissue in the body. Leptin deficiency in the body causes obesity and fatty liver, and it is a hormone produced to suppress appetite when excessive energy intake is consumed, and is used as an indicator of obesity. On the other hand, adiponectin is a hormone secreted from adipocytes and is involved in fat and glucose metabolism, and shows a negative correlation with the body mass index. It has been reported that the level of adiponectin decreases in obesity or metabolic syndrome with high neutral fat in the body.
실험 결과, 고지방식이 투여로 대조군의 렙틴 함량은 정상군 대비 유의적으로 높게 나타났으며 실시예 1 추출물의 모든 농도 투여군에서 렙틴의 함량은 대조군 대비 유의적으로 낮은 경향을 나타내었다. As a result of the experiment, the leptin content of the control group administered a high-fat diet was significantly higher than that of the normal group, and the leptin content in all concentration administration groups of the extract of Example 1 tended to be significantly lower than that of the control group.
한편, 고지방식이 투여로 대조군의 아디포넥틴 함량은 정상군 대비 유의적으로 낮게 나타났으며, 실시예 1 추출물 5, 25 ㎎/㎏ 투여군은 유의적인 차이가 없었으나, 250 ㎎/㎏ 투여군에서 대조군 대비 유의적으로 높은 수치를 나타내었다 (도 3). 도 3은 본 발명에 따른 자색옥수수 색소5호 추출물의 체중조절 관련 호르몬인 렙틴(leptin) 및 아디포넥틴(adiponetin)에 관한 분비조절 효능을 확인한 결과이다.Meanwhile, the adiponectin content of the control group was significantly lower than that of the normal group due to high-fat diet administration, and there was no significant difference in the groups administered 5 and 25 mg/kg of the extract of Example 1, but the 250 mg/kg group showed a significantly higher value than the control group (Fig. 3). Fig. 3 is the result of confirming the secretion regulation efficacy of the purple corn pigment No. 5 extract according to the present invention on leptin and adiponectin, hormones related to weight control.
Claims (10)
상기 에탄올 추출물 및 이의 에틸아세테이트 분획물은 췌장 리파아제에 대한 저해능을 가지는 것을 특징으로 하는 비만 예방 또는 치료용 약학 조성물.
Contains purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) ethanol extract and ethyl acetate fraction thereof,
A pharmaceutical composition for preventing or treating obesity, characterized in that the ethanol extract and the ethyl acetate fraction thereof have an inhibitory effect on pancreatic lipase.
상기 에탄올 추출물 및 이의 에틸아세테이트 분획물은 췌장 리파아제에 대한 저해능을 가지는 것을 특징으로 하는 비만 예방 또는 개선용 식품 조성물.
Contains purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) ethanol extract and ethyl acetate fraction thereof,
A food composition for preventing or improving obesity, characterized in that the ethanol extract and the ethyl acetate fraction thereof have an inhibitory effect on pancreatic lipase.
상기 에탄올 추출물 및 이의 에틸아세테이트 분획물은 췌장 리파아제에 대한 저해능을 가지는 것을 특징으로 하는 다이어트 보조제.Contains purple corn ( Zea mays L. ) pigment No. 5 (variety protection application number: application 2021-185) ethanol extract and ethyl acetate fraction thereof,
A diet supplement characterized in that the above ethanol extract and the ethyl acetate fraction thereof have an inhibitory effect on pancreatic lipase.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230190247A KR102759447B1 (en) | 2023-12-22 | 2023-12-22 | Zea mays L. pigment No. 5 extract or fraction thereof and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230190247A KR102759447B1 (en) | 2023-12-22 | 2023-12-22 | Zea mays L. pigment No. 5 extract or fraction thereof and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102759447B1 true KR102759447B1 (en) | 2025-01-24 |
Family
ID=94384886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020230190247A Active KR102759447B1 (en) | 2023-12-22 | 2023-12-22 | Zea mays L. pigment No. 5 extract or fraction thereof and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102759447B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100692560B1 (en) | 2004-06-18 | 2007-03-13 | 한국식품연구원 | Anti-obesity Amylase Inhibitors and Uses |
| KR20140117541A (en) * | 2012-01-16 | 2014-10-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Compositions and methods for treating diabetes and/or obesity |
| KR101676297B1 (en) | 2014-08-07 | 2016-11-15 | (주)주환바이오.셀 | Composition for supressing of blood sugar level |
-
2023
- 2023-12-22 KR KR1020230190247A patent/KR102759447B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100692560B1 (en) | 2004-06-18 | 2007-03-13 | 한국식품연구원 | Anti-obesity Amylase Inhibitors and Uses |
| KR20140117541A (en) * | 2012-01-16 | 2014-10-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Compositions and methods for treating diabetes and/or obesity |
| KR101676297B1 (en) | 2014-08-07 | 2016-11-15 | (주)주환바이오.셀 | Composition for supressing of blood sugar level |
Non-Patent Citations (3)
| Title |
|---|
| 2020년도 농업과학기술 연구개발결과 영농활용자료 (2020.)* * |
| JOURNAL OF AGRICULTURAL, LIFE AND ENVIRONMENTAL SCIENCES, 33(3), pp.339~346 (2021.12.31)* * |
| 공개특허공보 제10-2014-0117541호(2014.10.07.)* |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR19980702533A (en) | Anti-obesity agent with procyanidin as active ingredient | |
| KR102110040B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts | |
| JP2012051940A (en) | Beverage/food and medicine comprising loquat leaf extract | |
| US20250205263A1 (en) | Oral composition comprising b-escin and the use thereof | |
| JPWO2006135084A1 (en) | Preventive or therapeutic drug for steatohepatitis or fatty liver | |
| KR101672274B1 (en) | Compositions comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity | |
| KR102759447B1 (en) | Zea mays L. pigment No. 5 extract or fraction thereof and uses thereof | |
| KR101160088B1 (en) | Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover | |
| KR20040084168A (en) | Use of pinitol or chiro-inositol for preventing or treating liver diseases | |
| AU2004206156B2 (en) | Blood pressure-lowering agent, vascular flexibility-improving agent and foods having these functions imparted thereto | |
| KR101436213B1 (en) | Compositions for prevention and/or treatment of obesity comprising extracts of Boehmeria sieboldiana | |
| KR102239066B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component | |
| KR20190102681A (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component | |
| KR101695299B1 (en) | Composition for preventing or treating obesity or hyperlipidemia containing Piper longum extract, soy extract containing isoflavon and L-carnitin | |
| KR100685472B1 (en) | Composition for preventing and treating type 2 diabetes and metabolic syndrome using vinegar processed ginseng | |
| KR20110121239A (en) | Composition for the prevention or treatment of lipid metabolism disease comprising onion peel extract as an active ingredient | |
| KR101168595B1 (en) | A composition comprising an extract of Portulaca oleracea for preventing or treating diabetes, diabetic complications | |
| KR20150050780A (en) | Compositions for prevention and treatment of obesity comprising Litsea japonica extracts or fraction thereof | |
| KR102500342B1 (en) | Composition for preventing, ameliorating or treating hypercholesterinemia containing Cannabis sativa stem extract as effective component | |
| KR20190083071A (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising Cydonia sinensis leaf extract as effective component | |
| KR100473529B1 (en) | Composition comprising an extract of sungisan crude drug complex as an effective ingredient for preventing and treating diabetes | |
| EP3620166B1 (en) | Composition for anti-obesity comprising the pulverized material of odontella aurita as an active ingredient | |
| KR101987971B1 (en) | Composition for Preventing or Treating Arthritis, Comprising Aromatic Ketone Compound, Melicope pteleifolia Extract, or Fraction Thereof Containing the Same | |
| KR100478150B1 (en) | Health care food comprising an extract of the crude drug complex as an effective ingredient for preventing diabetes | |
| KR20240032213A (en) | Composition for preventing, ameliorating or treating hypercholesterinemia comprising Acer palmatum Thunb leaf extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20231222 |
|
| PA0201 | Request for examination |
Patent event code: PA02011R01I Patent event date: 20231222 Comment text: Patent Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20240131 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240314 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241128 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250120 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250121 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |